The Food and Drug Administration (FDA) recently approved a new indication for cemiplimab combined with chemotherapy as a first-line treatment for patients with advanced NSCLC, regardless of PD-L1 expression or tumor histology [31]. Here, CD274 is linked to non-small cell lung carcinoma.